1.00
+0.0358(+3.71%)
Currency In USD
| Previous Close | 0.96 |
| Open | 0.96 |
| Day High | 1.04 |
| Day Low | 0.95 |
| 52-Week High | 3.55 |
| 52-Week Low | 0.85 |
| Volume | 719,311 |
| Average Volume | 506,029 |
| Market Cap | 46.67M |
| PE | -1.1 |
| EPS | -0.91 |
| Moving Average 50 Days | 1.14 |
| Moving Average 200 Days | 1.33 |
| Change | 0.04 |
If you invested $1000 in PDS Biotechnology Corporation (PDSB) 10 years ago, it would be worth $2.84 as of October 08, 2025 at a share price of $1. Whereas If you bought $1000 worth of PDS Biotechnology Corporation (PDSB) shares 5 years ago, it would be worth $431.03 as of October 08, 2025 at a share price of $1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
GlobeNewswire Inc.
Sep 18, 2025 12:45 PM GMT
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS 1-19* Encouraging efficacy signal observe
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ann
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
GlobeNewswire Inc.
Aug 25, 2025 12:30 PM GMT
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Aug. 25, 2025